registration, as Takeda, exciting for are today. phase clinical continuing the But other of benefit flexible supply This these maintain using year, stopped ensuring trials about to is leveraging you existing offices Ayako, nonessential need. At of are while thank war, from will the need and Since workspace humanitarian and a patients support our medicine our a are in trials, us medicines working, us that Thank can you our supporting lead to are Takeda. you, and optimism. enrollment everyone ensure a align times. had of available really that reinforce time, way decision pandemic our we to business a technology. patients our have our for joining XXXX Ukraine. by reminded incredibly time donation activities activities. renewed are values still collaborative made in in very will medicines activities made much, significantly in to on the Recently, new our at We the Russia, new a crisis many more the the uncertain for the product we At is moving essential same start values in into we with into are still in we all Ukraine, the fiscal phone, with very donations. be results. We In we enhanced earning see transformed which a humanitarian with and are embracing with our we new of medicines. the we a been also again a that offices monetary country and energy Russian to remarkable decision to regards of year clear life-saving to and that It and constantly the
continues in we to committed for energized where line we that and prospect X. situation evolve, the reputation are by brought our trust, respond proud really with business I with in Starting As through today to to order. values patient action am our Slide future. are the of
future people health to decades the growth better world purpose for us create core of is come. foundation brighter will a create Our strategy to for a and value global for and help our
this oncology, growth growth includes plasma-derived with of Growth Launch we Within and products. and our neuroscience, that balanced drivers Our starts portfolio, rare and diverse strategy category vaccines. that genetics and gastroenterology, therapies are a have we hematology, portfolio our calling
our strategic will a expand in a China our launch global for many excellence, And capabilities expansion of focus focus optimizing We making geographic division in progress on product Portfolio most elevating execution commercial in Global important already moment. is our new medicines. on through significant growth, more our and this
You the have into can of we as China example as we markets. that best look potential new at expand the
X most biopharmaceutical the past We are the of over leading years. with approval China any global company in
to the investment will revenue world years. to Our allow our next X largest in China the second in double in expect effectively in us the pharmaceutical market
medicines our stage commercial to Next, driven approximately a nurture clinical we engine. with leverage R&D XX by our momentum pipeline
partnerships. have approach of We through dynamic network our R&D and XXX holistic in-house to a capability a research over
gene presence serious a how the and life-threatening to we in We therapies cutting-edge have and disease. building treat redefine cell that potential continue invest in to
coming the of proof multiple data over have opportunities with critical We exciting on quarters. concept study pivotal
the We our of pipeline programs potential are late-stage in our confident deliver development. commercial the term in in XX with to of medium
strong to this of thanks foundation. financial all possible, is Finally, our
focus margin. We on profit to competitive revenue growing continue our core and delivering a operating
which to drivers and It us also invest I cash patients. our in while allow our in buybacks to day, down progress Our to to our debt. well-established commitment dividend to and growth. share our the growth people of paying strong margin also the They allows living our appropriate. on cash world important values when return around credit form our drive for flow, each come shareholders work us
an are to experience people We colleagues work. to working deliver our exceptional continuously they all wherever
the that and of creative reinforcing to while way the value people collaboration. human We working power of and flexibility workspace are our redesigning provide our connection
future are are more creating data of generation. we are future, make think And to organization. ramping that reminded our about digital up and a of build sustainable programs the sure we importance planet we also to better We for our future-ready also foster systems when a the mission and resilient, learning health
others We our the community ambitious and sustainability journey us. with our in are challenge continuous a colleagues for on to
Our work before, than in great time of important uncertainty. particularly is more ever the
in revenue was business of growth of acceleration line with a by the increase XX.X%. product This challenge. On year-on-year is and was for our 'XX is with spite We growth on remain top the billion year the basis, well significant On Slide planet. a reinforce clear possibilities Fiscal our underlying was driven have long-term performance of our to X, launch year as patients, in strong line fiscal top positioned year for working. a look XXXX unlimited that today, which growth. revenue that delivered our make of growth will performance COVID-XX business key people future, it ¥X,XXX we we areas our X.X%. you reported As to strategy see across an impact
momentum robust the also us paying shows debt commercial and cash generate adjusted X.Xx. in free to reaching us solid financial of significant EBITDA ¥XXX.X to while develop continued also pipeline potential. to net allow our allowed debt, which with continue We invest billion, to that growth a a ending year This down foundation ratio drivers flow, to
we the organization, doing to build for we are science-driven that. a are and committed future, As
EXKIVITY proving new even in geographies. are patients, momentum. our Notable bring launch have more new added and products therapies launch indication approvals, and and We exceeded ability LIVTENCITY expectation to to expand
start We within to Let's in U.S. days strong are of start. the launched off with a approval and EXKIVITY.
administration. half to numbers EXKIVITY treatment of new is branded broad capturing among fact, prescribing response be can XX attributed individual EXKIVITY's In starts and The patient approximately options. high prescribers Exon all the use X and durable overall EGFR of
We are approval in expanding and the new reaching with markets conditional are new U.K. patients into EXKIVITY recent the
More with months LIVTENCITY post-transplant have patients prescribed the following XXX treated in the in which We LIVTENCITY, antiviral treatment, and are U.S. than been with similar This the in of the seeing launched approximately grow. infection XX% to XXX is our demand December launch, continuing success XXXX. To in the centers U.S. more have transplant the unique value LIVTENCITY. to speaks LIVTENCITY. date, than of
LIVTENCITY patient, manufacture will the patient has month, we distribution recently analysis fiscal license and continuing vaccines to Japan. data in we been remarkable. showed we in address that EXKIVITY of bring needs. the effort we COVID-XX rate is an people Last are traction soon important are and help the Japan. year addressing announced and of begin in NUVAXOVID seeing reduction are We to exploratory to gain hospitalization are approval This and both of making. also It To pandemic, received distinct our impact Patient to length clear that and meaningful stay. by hospital LIVTENCITY past
past X are demonstrated We proud talked GammaDelta of about in Adaptate Maverick most history, a I've year innovative have example in our robust in to immuno-oncology our of therapies received The companies, action. complement expertise number approvals new Therapeutics, in our how Therapeutics patients. of approval innovative network during and Japan. passively of ability the clearly R&D the fiscal respected our we and serve of bring strategy to We our and leading to with global industry acquisition partners. be the in we highest Biotherapeutics any in-house as a great some drug
with Pharmaceuticals Another collaboration treat this agreement and a living JCR new to license maintain in develop patients disease. way rare committed great or a syndromes improve Hunter example help to function is with and
Slide We vaccine Frazier to We the in launch it best a year to innovation biopharmaceutical unlock collaborate develop and company science collaboration fiscal to Healthcare with candidate. have HilleVax, a wherever follow and norovirus Takeda also revenue announced Partners growth strong 'XX commercialize offer to opportunities our partnerships new of These our to than advance will continue ahead On looking fiscal that and exciting X, pipeline. will more exclusivity. originates. we from expect XXXX, loss impact year offset
we give use divestiture of operating methodology, completed, basis, forward, on will exchange management constant guidance the CER Going for we a program for of had digit, Previously, foreign core as the complex because we to low underlying foreign essentially -- digits only to expect low revenue used exchange. high growth, end a profit EPS our rate adjusting we single grow well at exchange. on as But at divestiture which we and financial. exchange will rate, adjusted core On grow more single expect or our digits. is core constant to concept high single be core now
of the continue with to core ¥X cash operating for time a expect flow. trillion, We ever, Takeda delivering first EPS robust first ¥XXX. forecasting core for profit a the And exceeds are that
our alongside of We share remain dividend With continues pipeline diverse our EPS when priority. also increase reported to share expect a committed to we appropriate. to maintaining with rebound basis, to shareholder policy XX.X%. earnings on Developing returns, a reported buyback per by regards a be annually, well-established ¥XXX
highlights. We upcoming I'd few have point near-term and us exciting many development XX to expansion programs late-stage opportunities NMEs with like to of filing front with opportunities. a in
endemic TAK-XXX should IQVIA dengue, that filing Our in spreading data XX of CIDP, decision opportunities include XXXX. by label anticipate WHO Other readout late-stage opportunities dengue in demyelinating We for inflammatory thrombocytopenic the in and dengue to European year vaccines, cytomegalovirus allow have XXXX borne the data one best-in-class global future a thrombotic we chronic as countries congenital label for this for authorities health. the cover. TAK-XXX LIVTENCITY this in with frontline with is we believe review fastest purpura. various top milestones infection, for vaccines fiscal mosquito late-stage and under currently to in and named year disease, threats CTTP, readout indication The expansion polyradiculoneuropathy, in public expansion with a
Slide continuing In across be and the with to next to turn program, of impressive Orexin on area growth pipeline X multiple the proof-of-concept the which approval we coming condition. like we life-threatening positive to years, remain develop additional data on franchise, will for that impact there see driving is lead readouts expect our business decade. the I'd next patients an over our a could focused to later this particular, in year. TAK-XXX, oral to On making now X, Finally, and
of the performance the continued year revenue than driven of players. say XXXX This given major the Our by I'm that albumin. calendar that faster achievement in was market, total pressure challenge pandemic grow is and the to PDT remarkable our to portfolio immunoglobulin strong highest industry proud greatly the a industry. the the of growth
grew you can XX% and see grew year-over-year. rate immunoglobulin As X% at here, albumin of a
transform attributed patients are Throughout capabilities. Our and operation require remarkable and diagnosed continuity be brought donation efforts on growth maintain the pandemic, to been patient objective in, to consistent to volume therapy. our has can growth supply, to end-to-end plasma invest of primary which new expand our and our as
We commitments year. all worldwide fiscal in the our met have past patients to supply
with that ahead, anticipate growth have. past and XX%. we XX immunoglobulin X and demanded PDT between plasma, in more and our years growth have portfolio albumin see Looking and both we of do The for and XX% business we XX -- potential less our of
start to to we capture transformation the We enable prepandemic organizational moderate year-over-year donors and expect over are levels margin of full to digital time. to improve the to compensation benefit to Indeed, well U.S. PDT in margin business improvement. also our positioned of closer
We to advance return have XXXX. manufacturer and were in mitigate plasma already plasma donation to pre-pandemic efficiencies and done operational fiscal costs digital. also through additional to the volumes much plasma XX% in donation year data fully first expect to major We XX% and an deliver growth to volume
meet and working. with bottom is PDT Strong has commitment. here top paired optimization maintain enabled growth our successfully growth strategy to our line trajectory line Our
I our portfolio. commercial like we with Next, classifying would how are on to Slide X, you share
This Moving future It our includes in drivers growth ALUNBRIG fiscal and billion immunoglobulin under and products. forward, billion TAKHZYRO, at product. XX%. revenue generated of we Launch and underlying in products year will delivered most important ¥XXX a last our or ENTYVIO, look growth category USD global incremental called and and category Growth albumin X
of unmet our newest our address at revenue future revenue. of approval of growth. EXKIVITY in look also and drivers put including the of will to allow LIVTENCITY on needs, launch our products as one growth patients by is but specific illustrated bring We markets, These product to category, global new slight expanding the growth in a us XX as Japan. ALUNBRIG from This that This that of this and emphasizes source and our launches, focus driver represents adjustment majority China launches future and TAKHZYRO brands, previous our rapidly and main important in and vast growth. represent revenue new value to on strategic X/X the global are substantial recent
this to to underlying addition we slightly to and evolution. exchange In change shift from adjusting business our reflect how also the rate, describe are our we constant future-forward pipeline
Slide business reinforcing our see all that generate to simplicity growth to we and key next new to reflected readout. immunoglobulin our on slide life on cycle like I decade. our intended start this pipeline with shortly. of and and on the will the with are our of our be in late-stage ahead, X, product On will ENTYVIO, reporting the all expected we continuing years. place and end clarity pipeline, the would albumin Looking portfolio show substantial emphasizes presentation direction pipeline, by adjustments coming the management This TAKHZYRO, proof-of-concept This in into
growth are in of will like us significant X impacted. be confident VYVANSE that drivers allow which especially impact VELCADE, losses from products will is next the as years offset to these We AZILVA and the coming exclusivity,
VYVANSE Even growth As compound revenue will consequence, and single-digit we we to low our in range a fiscal likely XXXX, face the in year be 'XX when expect 'XX. between annual rate year, portfolio generic that the that are entry The we flat. facing temporary. August the there headwinds momentum from rest to coming hold believe is revenue of approximately enough are in we
ENTYVIO important it we that after we remember We exclusivity significantly the exclusivity half second and manage U.S. in headwinds we the not launch face As loss decade. until lower do think is loss loss VYVANSE, future can we biosimilars 'XX, this magnitude of the 'XX, exposure long-term outlook, the of the of this exposure about of exclusivity to in of expect of have in
expect any expiration. not of do at exclusivity we time biosimilar the communicated, to previously for As see ENTYVIO entry that
launch to patents and patents. to We infringement ENTYVIO that run ENTYVIO biosimilar seeks to prior that of need validity any all then potential relevant have out or XXXX address of to for the will
and And new and PDT our any our biosimilars As and to infrastructure onto or This at products deliver digital, we today, it to is launch while we stands we EBITDA a the our Xs margin of fiscal organically leverage targeted yet low either expansion adjusted in continued to investments data minimize and 'XX clinical aim development. cost or also have also business see competitive, as turn, core impact in investing margin on generics our year operating development. improved the continue to of through R&D our deleverage towards profit VYVANSE pipeline in above will, enriching level. us target and growth our allow
that connected to relentless success of We our XX. values. lose can Slide the our and patients our on focus fact underlying sight to Moving never be
life-transforming to by life-transforming our purpose-led commitments significant planet. deliver potential digital. will drives the discovery, aided our and in and and treatment. for see future, to better outcome we work. value-based look is will decision. all our This transform delivery experience patients, is to as of we the data we patients, people, And our -- business discover development action and vision and the way revolutionizing and treatments already and and I the Our accelerating create revolutionize Technology And approach
medicines in treatment is areas year. proud continue a need as a to brought growth as in to with company. to on fiscal challenge scientific last most business our new We key trusted, the ability our our This area. and life Takeda grow option. desperate patients, make Our can values our impact continue well digital greatest to effective where there own I'm goal transforming biopharmaceutical we disease, In summary, patients saw into science-driven and advancement year for ambition. focus remarkable really our for is was progress strong lead including of rare where We to the
continue recent generate innovation. are organic approval, line more execution, our of with fuel combined confident even growth. the of flow us position pipeline, Our to potential to long-term to help cash steady diverse also fuel our and strength that we to top today competitive performance while portfolio future strong margin the our driving will commercial With will our
in We expect fiscal geographic expansion, as penetration, growth particularly momentum new China. markets to year continue next and through indication market such
outlook I will and R&D you. to discuss that provide We exciting to opportunity pipeline. this growth the that, Andy to With societal business are like our mid- term. with value long signify would confident Thank an in
